Business Wire

Greek National Organization of Medicines Approves First Antimicrobial Formula for Residual Surface Protection Against SARS-CoV-2 (COVID-19 Virus) for up to 90 Days

14.7.2021 09:15:00 EEST | Business Wire | Press release

Share

ViaClean Technologies, LLC, a Philadelphia-based biotech company, jointly with its distributor and business development partner, Bizos Cavallo Enterprises LLC of Dallas, TX, and their partner, V-Clean Technologies S.A. of Athens, Greece, jointly announced the country of Greece's approval for the use of BIOPROTECT™ RTU on porous and non-porous surfaces in the fight against SARS-CoV-2. Greece has recognized BIOPROTECTTM RTU as inhibiting the growth of harmful bacteria and viruses, including SARS-CoV-2 (COVID virus), on surfaces for up to 90 days.

Having accepted and recognized the antimicrobial surface efficacy of BIOPROTECT™ RTU, Greece's National Organization of Medicines (ΕΟΦ) has approved the unrestricted consumer use of BIOPROTECT™ RTU to inhibit the growth of SARS-CoV-2 and other harmful viruses, bacteria, mold, and mildew, on treated surfaces. This innovative technology has proven to be effective for up to 90 days and has been applied in various public and private environments in Greece, including medical facilities, mass transit, education, commercial facilities, and more.

"ViaClean has been committed to supporting the reopening of Europe throughout the past year, hoping to instill a sense of normality as people navigate these unprecedented times," said ViaClean President and CEO, Greg Tipsord. "With Greece's adoption of BIOPROTECTTM RTU antimicrobial surface protectant, which inhibits the growth of SARS-CoV-2 and other harmful viruses and bacteria on surfaces, we believe Greece will benefit from this proven technology and strengthen their commitment to reach pre-pandemic levels of normalcy for their citizens. We've delivered an effective antimicrobial surface protectant solution that supports our mission of continued research, innovation, and dedication on a global scale."

"At V-Clean Technologies S.A., we have further cemented our commitment to Greece and the ongoing safety of our fellow citizens and visitors through our commitment to bringing innovative, patented technologies to our country to reduce the presence of bacteria, germs, fungi, algae, and other problematic micro-organisms including SARS CoV-2” said Panos Sofianos, President of V-Clean. “We thank the Greek government, and specifically the Ministry of Health and the National Organisation for Medicines (ΕΟΦ), our joint-venture distribution partner, Bizos Cavallo Enterprises and of course, ViaClean Technologies, for their rigor, diligence, and support throughout this process."

In Greece and in other European Member States, where regulatory approvals are pending, the unique non-leaching and non-volatile BIOPROTECTTM RTU formula has proven to be effective at killing harmful microbes and reducing odors for up to 90 days on various surfaces. "We are fortunate and thrilled to have partnered with both V-Clean Technologies and ViaClean Technologies by facilitating the approval process and distribution of BIOPROTECTTM RTU antimicrobial surface protectant for Greece," said Elvin Thibodeaux, Managing Partner of Bizos Cavallo Enterprises. "Our continued efforts will supply this innovative technology exclusively to additional markets, including the European Union and Balkan Peninsula, Russia and more, that are pursuing dynamic relief from the effects of the pandemic over the past 18 months."

In the United States, ViaClean markets the BIOPROTECTUs™ System, which uses patented, registered technologies: SmartTouch®, a List N disinfectant, to disinfect surfaces against viruses, bacteria, and germs, and BIOPROTECT™ RTU antimicrobial surface protectant, to keep surfaces free of odor- and stain-causing bacteria, fungi (mold and mildew), and algae between cleanings, for up to 90 days (3 months). In the United States, however, BIOPROTECT™ RTU is not currently approved or available for use against the SARS-CoV‑2 virus, other viruses, harmful bacteria, or any other harmful microorganisms.

Additional products offered from ViaClean and Bizos Cavallo in the United States, and pending approval in Greece, include the registered BIOPROTECT™ 500 concentrate, registered BIOPROTECTTM D disinfectant, and registered BIOPROTECT™ Hydrating Hand Sanitizer. For more information on ViaClean Technologies and The BIOPROTECTUs™ System, please visit bioprotectworldwide.com. For information on the aforementioned markets or sales with Bizos Cavallo Enterprises, visit www.bizoscavallo.com.

About ViaClean Technologies. LLC

ViaClean Technologies LLC is a biotech company that develops, manufactures, and markets groundbreaking, innovative antimicrobial solutions using environmentally responsible manufacturing processes. ViaClean Technologies' pioneering and proprietary technologies, products, and services provide disinfectants, antimicrobial protectants, and hand sanitizers for commercial and consumer use. ViaClean Technologies' primary mission is to market these advanced antimicrobial formulations to critical industries, manufacturing the registered formulations using environmentally responsible processes. For more information, visit the ViaClean website (bioprotectworldwide.com).

About V-Clean Technologies, S.A.

V-Clean Technologies S.A. is a biotechnology firm based in Athens, Greece that is focused on developing and marketing cutting edge technologies, products and services to meet the challenges and opportunities in Europe, Russia and the Middle East. In conjunction with our pharmaceutical affiliates and partners we strive for innovative and environmentally responsible solutions in an ever-changing marketplace. Having created a strong and sustainable network of strategic partners throughout these regions, we are able to be proactive and effective in providing services ranging from manufacturing, sourcing, logistics and regulatory advisory. For more information about V-Clean Technologies S.A. please visit our website (www.virusclean.gr).

About Bizos Cavallo Enterprises, LLC

Bizos Cavallo Enterprises, LLC is a strategic consulting and operations firm focused on emerging bioscience innovations for public health, strategic alliances, and global investment resources based in Dallas, TX, with offices in New Orleans, LA, and Winston-Salem, NC. In addition, Bizos Cavallo owns the subsidiary, BP&D International, LLC, a global leader in the procurement and the export of premium cultural commodities, including bulk grains, animal proteins, and their respective derivatives. Founded in 2017, Bizos Cavallo's network includes partners and a host of strategic alliances in the United States, Greece, China, South Korea, Japan, Singapore, Dubai, France, Brazil, the West Indies and trade operations in the United Kingdom. For more about Bizos Cavallo, visit the Bizos Cavallo Enterprises website (www.bizoscavallo.com).

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media
Chad Belisario
EVINS Communications
Email: ViaClean@evins.com

Chad Belisario
Bizos Cavallo Enterprises, LLC
Email: media@bizoscavallo.com

Chad Belisario
V-Clean Technologies, Ltd
Email: Info@virusclean.gr

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte to Highlight Late-Breaking Hidradenitis Suppurativa Data at the 2026 American Academy of Dermatology (AAD) Annual Meeting20.3.2026 16:00:00 EET | Press release

Incyte (Nasdaq:INCY) today announced that data from key programs in its Inflammation and Autoimmunity (IAI) franchise will be presented at the 2026 American Academy of Dermatology (AAD) Annual Meeting, to be held March 27 – 31, 2026, in Denver. “At AAD 2026, we are presenting late‑breaking 54-week results from the Phase 3 STOP‑HS program evaluating povorcitinib in hidradenitis suppurativa (HS),” said Jim Lee, M.D., Ph.D., Group Vice President, Inflammation and Autoimmunity, Incyte. “These data provide longer term evidence of the safety and efficacy of povorcitinib in HS patients and further strengthen the significant growth potential of our Inflammation and Autoimmunity franchise.” Details on key data presentations at AAD include: Late-Breaking Oral Presentations Hidradenitis Suppurativa Povorcitinib in Patients With Moderate to Severe Hidradenitis Suppurativa: 54-Week Efficacy and Safety Results From the STOP-HS1 & STOP-HS2 Phase 3 Studies (Session: S034 – Late-Breaking Research: Sess

MUSASHI JAPAN by TAIMATSU Launches “Road to Shogun” – A Journey Through Craftsmanship and Discovery20.3.2026 14:58:00 EET | Press release

Musashi Japan by TAIMATSU Co., Ltd., a contemporary Japanese knife brand rooted in the spirit of craftsmanship and cultural harmony, has announced its newest experiential campaign: “Road to Shogun.” This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260320887471/en/ Designed as the brand’s most ambitious customer journey to date, the campaign invites visitors to explore participating Musashi Japan stores while discovering the traditions, culture and craftsmanship that inspire the brand. Inspired by the journey towards mastery, the experience encourages participants to progress through a series of ranks whilst visiting stores and unlocking rewards that celebrate elements of everyday Japanese culture. At Musashi Japan, craftsmanship is not only about the final product, but also about the path taken to achieve mastery. The Road to Shogun reflects this philosophy by guiding customers through a journey that mirrors the dedication, cu

Futur Delivers Strong Growth and Record Profit in 202520.3.2026 13:05:00 EET | Press release

"2025 was a record year for Futur. In a market characterized by sharp market fluctuations, Futur continued to invest, grow and deliver strong results. Behind this record performance is stable customer growth, strong inflows and cost discipline. Our close cooperation with over 60 partners gives customers the freedom to choose the asset management and advisory services that best suit them. The strategy of letting the customer choose is appreciated, which is reflected in us welcoming more than 21,000 new customers during the year", says Torgny Johansson, CEO of Futur. "We are optimistic about the future. Futur has great opportunities to continue growing in the coming years by developing innovative and efficient services for savings and pensions. I am proud of how all employees have purposefully embraced our strategy and continue to work towards the goal of reaching 500 billion kronor in savings capital with the current organization", concludes Torgny Johansson, CEO of Futur. Key highlight

Lyten to Establish a Lyten Industrial Hub in Poland20.3.2026 13:00:00 EET | Press release

Lyten, the supermaterial applications company and global leader in an energy storage, has announced its interest in establishing a Lyten Industrial Hub in Poland. In 2026, Lyten will conduct a feasibility study to assess manufacturing requirements for Lyten products, potential private and public partnerships, and the necessary energy and utility infrastructure. The industrial hub will be built around Lyten Dwa – the energy storage production plant and R&D center in Gdańsk. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260320045026/en/ Lyten Voltpack Mobile System in front of Lyten Dwa plant in Gdansk, Poland In February 2026, Lyten announced the establishment of its first Industrial Hub in Skellefteå, Sweden, on the site of the former Northvolt Ett plant, which it recently acquired. It will combine battery production with a data center with a capacity of up to 1 GW, being built by EdgeConneX. Once it reaches full production

PUMA Reveals Its Most Powerful International Football Kit Lineup yet on the Streets of New York City20.3.2026 09:00:00 EET | Press release

Global sports company PUMA unveiled its new national team kits for 11 nations with a street-level event at Domino Square in New York City, that placed football, music, food, and culture at the center stage in a celebration of the game. Rather than launching in a stadium setting or in a cinematic brand film, PUMA chose to reveal the kits in play, worn first by local community players from each nation on the streets of New York. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260320641449/en/ Reinforcing its status as a leading force in football kits at this summer’s competition, PUMA unveiled jerseys for 11 nations, including the most prominent African partner federations of any brand in the tournament, in a community-first celebration of football, music, and culture in New York City. Four continents are united under 11 nations: Portugal, Morocco, Ghana, Paraguay, Senegal, Côte d’Ivoire, Czech Republic, Switzerland, New Zealan

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye